Harmanpreet Chawla

Dr. Harmanpreet Chawla

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2020 in Cureus
Verified
Journal Article
Open access
PDF file
HCHarmanpreet Chawla
Harmanpreet Chawla
TWThomas Weiler
Thomas Weiler
A 15-year-old male with a history of mild intermittent asthma presented with fatigue, coughing, vomiting and anorexia which was progressive in nature over the past month. The patient was found to have evolving chest x-ray infiltrates bilaterally, and hypoxemia without accessory muscle use. The patient was placed on non-invasive continuous positive airway pressure (CPAP) for hypoxemia. A CT scan showed bilateral infiltrates in a pattern consistent with E-cigarette or Vaping product use-Associated Lung Injury (EVALI). Upon further history taking, the patient admitted to electronic cigarette (e-cigarette) use with a new tetrahydrocannabinol (THC) cartridge prior to the onset of symptoms. The patient was started on methylprednisolone after which his oxygen requirement improved. This case highlights the need to continue to be diligent regarding the use of e-cigarettes in the pediatric population, and be aware of the constitutional symptoms that are associated with their use.

3 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TSTrisha Sunderajan
Trisha Sunderajan
SCShira Choi
Shira Choi
CLCaroline LaFerla
Caroline LaFerla
RGRobert Daniel Guglielmo
Robert Daniel Guglielmo
HCHarsha Kailash Chandnani
Harsha Kailash Chandnani
MGMichael Giang
Michael Giang
Background: Routine chest X-rays (CXR) are not recommended by the American Academy of Pediatrics in bronchiolitis, yet remain a mainstay in diagnostics. We aimed to understand the impact of obtaining CXRs in patients with critical bronchiolitis, assessing intensive care unit length of stay (ICU-LOS) and intensive care unit level of respiratory support (ICU-LRS). Methods/Design: This single-center retrospective cohort study assessed children less than three years of age admitted to the PICU, pediatric step-down ICU, and pediatric cardiac ICU. Two groups were used for analysis: patients with CXR and no-CXR. The primary outcome was the difference in ICU-LOS and ICU-LRS between the groups. The critical bronchiolitis score (CBS) was used to calculate a predicted ICU-LOS and ICU-LRS. The secondary outcome was the difference between actual and predicted ICU-LOS and ICU-LRS, comparing the groups. Results: Of the 107 patients included, 65 patients (61%) received a CXR. Patients who received a CXR had significantly longer ICU-LOS (p = 0.01) and ICU-LRS (p = 0.02), despite no difference in predicted illness severity (ICU-LOS, p = 0.4; ICU-LRS, p = 0.3). The difference between actual and predicted ICU-LOS was greater in the no-CXR group (–1.4 days) compared to the CXR group (–0.8 days; p = 0.04). A similar trend was observed in ICU-LRS (–0.1 vs. –0.6 days; p = 0.1), though not statistically significant. Conclusions: Routine CXRs are common in critically ill bronchiolitis patients and may be associated with longer ICU-LOS and ICU-LRS, despite similar illness severity.

24 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
TSTrisha Sunderajan
Trisha Sunderajan
SCShira Choi
Shira Choi
CLCaroline LaFerla
Caroline LaFerla
RGRobert Daniel Guglielmo
Robert Daniel Guglielmo
HCHarsha Kailash Chandnani
Harsha Kailash Chandnani
MGMichael Giang
Michael Giang
Background: Routine chest X-rays (CXR) are not recommended by the American Academy of Pediatrics in bronchiolitis, yet remain a mainstay in diagnostics. We aimed to understand the impact of obtaining CXRs in patients with critical bronchiolitis, assessing intensive care unit length of stay (ICU-LOS) and intensive care unit level of respiratory support (ICU-LRS). Methods/Design: This single-center retrospective cohort study assessed children less than three years of age admitted to the PICU, pediatric step-down ICU, and pediatric cardiac ICU. Two groups were used for analysis: patients with CXR and no-CXR. The primary outcome was the difference in ICU-LOS and ICU-LRS between the groups. The critical bronchiolitis score (CBS) was used to calculate a predicted ICU-LOS and ICU-LRS. The secondary outcome was the difference between actual and predicted ICU-LOS and ICU-LRS, comparing the groups. Results: Of the 107 patients included, 65 patients (61%) received a CXR. Patients who received a CXR had significantly longer ICU-LOS (p = 0.01) and ICU-LRS (p = 0.02), despite no difference in predicted illness severity (ICU-LOS, p = 0.4; ICU-LRS, p = 0.3). The difference between actual and predicted ICU-LOS was greater in the no-CXR group (–1.4 days) compared to the CXR group (–0.8 days; p = 0.04). A similar trend was observed in ICU-LRS (–0.1 vs. –0.6 days; p = 0.1), though not statistically significant. Conclusion: Routine CXRs are common in critically ill bronchiolitis patients and may be associated with longer ICU-LOS and ICU-LRS, despite similar illness severity.

13 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
TSTrisha Sunderajan
Trisha Sunderajan
RGRobert Daniel Guglielmo
Robert Daniel Guglielmo
HCHarsha Kailash Chandnani
Harsha Kailash Chandnani
HCHarmanpreet Chawla
Harmanpreet Chawla
Objective: The role of bronchodilators in bronchiolitis remains unclear, yet they are commonly used. We evaluated their impact in children based on family history of atopy and viral etiology (RSV and rhinovirus). Methods: This was a single-center, retrospective study of children ≤ 2 years admitted to the PICU, step-down ICU, or cardiothoracic ICU who required high-flow nasal cannula, non-invasive ventilation, or invasive ventilation. Patients were categorized by bronchodilator use and stratified by family history of atopy. Primary outcomes were ICU and hospital length of stay (LOS) and length of respiratory support (LRS). The Critical Bronchiolitis Score (CBS) was used to adjust for illness severity by calculating predicted outcomes and comparing them with the observed values. Secondary analysis evaluated outcomes based on family history of atopy and RSV/ rhinovirus positivity. Results: Of 105 included patients, 56 (53.3%) received bronchodilators. The no-bronchodilator group had shorter ICU-LOS (1.7 vs. 2.5 days; p = 0.0005) and hospital LOS (2.1 vs. 3.4 days; p = 0.0038) compared to the bronchodilator group. Predicted ICU outcomes did not differ between groups. Secondary analyses suggested differences in ICU-LOS (p = 0.007) and hospital LOS (p = 0.02) based on family history of atopy. In rhinovirus-positive patients, both ICU and hospital LOS were shorter without bronchodilators, while no differences were observed in RSV-positive patients. Conclusions: Bronchodilators in critical bronchiolitis were associated with longer inpatient LOS, despite similar predicted illness severity. Neither a family history of atopy nor rhinovirus/RSV positivity affected bronchodilator outcomes. Future prospective research is needed to identify targeted subgroups of patients who may benefit from this therapy.